

Informed arm: biologic choice guided with Mind.Px report

TAU arm: biologic choice not report-guided



Inclusion criteria:  
lesion  $\geq$  2 cm in diameter, PASI  $\geq$  10, PGA  $\geq$  3

# 1:1 RANDOMIZATION, 200 PATIENTS TOTAL

Screening

Baseline  
(DBP)

Week 4  
(PASI, PGA, BSA, DLQI)

Week 8  
(PASI, PGA, BSA, DLQI)

Week 12  
(PASI, PGA, BSA, DLQI)

Week 16  
(PASI, PGA, BSA,  
DLQI, SF-36)

Randomization to informed or Treatment As Usual (TAU) arm



**APPLY SINGLE DBP**



**EXTRACT**



**SEQUENCE & ANALYZE**



## PATIENT REPORT

### PATIENT

Patient name: **John Doe**  
Sample ID: **0000000**  
Date of birth: **01/10/1965**

### ORDER

Date specimen collected: **03/10/2020**  
Date of testing: **03/28/2020**  
Ordering physician: **Dr. Janet Doe**  
Clinic/hospital: **Smallville Dermatology**  
**000 Street Name**  
**Smallville, KS**



## TEST RESULTS

**R**

Responder

**TNF $\alpha$  Inhibitor**

*Tumor Necrosis Factor Alpha*

**NR**

Non-Responder

**IL-17 Inhibitor**

*Interleukin 17*


**R**

Responder

**IL-23 Inhibitor**

*Interleukin 23*

$p = 0.02$



Identical trend between  
two control arms

Assessments	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5	Visit 6
	Screening 1-4 Weeks	Baseline/ Randomization	Week 4 ±3 Days	Week 8 ±3 Days	Week 12 ±3 Days	Week 16 ±3 Days
Informed Consent	<b>X</b>					
Inclusion/Exclusion Criteria	<b>X</b>					
Demographics	<b>X</b>					
Clinician Demographics	<b>X</b>					
Mind.Px Dermal Patch	<b>X</b>					
Medical History	<b>X</b>					
Biologic Treatment History (previous & current; including response and questionnaires)	<b>X</b>					
Current Biologic Treatment & Biologic Treatment Trials Since Last Visit (including response and questionnaires)		<b>X</b>	<b>X</b>	<b>X</b>	<b>X</b>	<b>X</b>
Medication History (other than biologics)	<b>X</b>					
Physical Exam	<b>X</b>					
Vital Signs	<b>X</b>					
Randomization		<b>X</b>				
PASI	<b>X</b>	<b>X</b>	<b>X</b>	<b>X</b>	<b>X</b>	<b>X</b>
PGA	<b>X</b>	<b>X</b>	<b>X</b>	<b>X</b>	<b>X</b>	<b>X</b>
BSA	<b>X</b>	<b>X</b>	<b>X</b>	<b>X</b>	<b>X</b>	<b>X</b>
DLQI		<b>X</b>	<b>X</b>	<b>X</b>	<b>X</b>	<b>X</b>
SF-36 (patient reported)		<b>X</b>				<b>X</b>
Clinician Utility Questionnaire*		<b>X</b> (after)				
Adverse Events (AEs)	<b>X</b>	<b>X</b>	<b>X</b>	<b>X</b>	<b>X</b>	<b>X</b>
IP accountability	<b>X</b>					
Dose Changes		<b>X</b>	<b>X</b>	<b>X</b>	<b>X</b>	<b>X</b>
Switching		<b>X</b>	<b>X</b>	<b>X</b>	<b>X</b>	<b>X</b>
Regimen Augmentation		<b>X</b>	<b>X</b>	<b>X</b>	<b>X</b>	<b>X</b>
Discontinuation		<b>X</b>	<b>X</b>	<b>X</b>	<b>X</b>	<b>X</b>
Biologic Compliance		<b>X</b>	<b>X</b>	<b>X</b>	<b>X</b>	<b>X</b>

	Mind.Px Informed	TAU
Concordant (%)	36 (87.8%)	21 (55.3%)
Discordant (%)	5 (12.2%) <sup>a</sup>	17 (44.7%)